Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Core Insights - Nanobiotix is a late-stage clinical biotechnology company focused on innovative physics-based approaches to enhance cancer treatment options for patients [1][3][4] - The company will participate in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 11, 2024, in New York City [2] Company Overview - Founded in 2003, Nanobiotix is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on Nasdaq since December 2020 [4] - The company holds over 25 patent families related to three nanotechnology platforms, which are applicable in oncology, bioavailability and biodistribution, and central nervous system disorders [4] Event Details - The fireside chat at the conference will feature Laurent Levy, co-founder and chairman, and Bart Van Rhijn, CFO of Nanobiotix [2] - The event will be webcast live, with a replay available afterward [2]